Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
The Body Covers:
The 8th Conference on Retroviruses and Opportunistic Infections
Sheraton Chicago Hotel and Towers, Chicago, Illinois

February 4-8, 2001



The 8th Conference on Retroviruses and Opportunistic Infections draws 3,200 clinicians and basic scientists from around the world to present the latest research on HIV, AIDS, and opportunistic infections. The meeting is sponsored by the Foundation for Retrovirology and Human Health and is in scientific collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Centers for Disease Control and Prevention (CDC).

The Retrovirus Conference, regarded as one of the most important scientific gatherings of the year, was created to provide a forum for scientists and clinicians to present, discuss, and critique developments in the field of human retrovirology and related opportunistic complications. The subjects that will be highlighted are: virology, pathogenesis, host-virus interactions, pathology, immunology, epidemiology, diagnostics, prevention, therapy, pharmacology, and vaccines. In addition, new scientific studies concerning the diagnosis, treatment, and prevention of associated opportunistic infections will be included.

Reporting exclusively for The Body are Brian Boyle, M.D., J.D.; Calvin Cohen, M.D., M.S.; Richard Alan Elion, M.D.; Judith Feinberg, M.D.; Keith Henry, M.D.; Andrew T. Pavia, M.D.; Paul E. Sax, M.D.; Pablo Tebas, M.D.; and Benjamin Young, M.D., Ph.D. For more information on these outstanding doctors, click on their pictures or on their names.

Funding for this conference coverage at The Body is provided, in part, by unrestricted educational grants from Bristol-Myers Squibb Company, DuPont Pharmaceuticals Company, Glaxo Wellcome Inc., Merck & Co., Inc. and Roxane Laboratories, Inc.


The Body's Conference Summaries
Day One
Monday,
February 5
Day Two
Tuesday,
February 6
Day Three
Wednesday,
February 7
Day Four
Thursday,
February 8

Viral Reservoirs and Ongoing Virus Replication in Patients on HAART

NeuroAIDS

Antiretroviral Chemotherapy I

Co-Pathogens and Opportunistic Infections

Immunology: Miscellaneous

CD4 and CD8 T-Cell Responses

Factors Associated with Disease Progression

Risky Behaviors/Detection of Infection

Transmission

Post-Exposure Prophylaxis

Diagnostics

Pharmacology of Antiviral Chemotherapeutic Agents

HIV-Related Peripheral Neuropathies and Their Treatment

Epidemiology and Infection Control

Maternal-Fetal Transmission of HIV-1: Implications for Care of HIV-Affected Women and Children

Structured Treatment Interruption: Novel Strategy or Oxymoron

Trends in Morbidity and Mortality

Antiretroviral Chemotherapeutic Agents: Preclinical Studies

Clinical Trials of HIV-1 Reverse Transcriptase Inhibitors

Clinical Trials of HIV-1 Protease Inhibitors

Antiretroviral Chemotherapy: When to Start

Immune-Based Therapy

Treatment Interruption

Immune Reconstitution

Viral Dynamics and Reservoirs

Treatment of Primary Infection

Clinical, Viral, and Immunological Features of Primary Infection

Drug Resistance in Primary Infection

Regimen Failure

Clinical Utility of Resistance Testing

Resistance to Antiretroviral Drugs

HIV Pathogenesis

Development of CCR5 Antagonists as a New Class of Anti-HIV Therapeutic

Antiretroviral Chemotherapy II

Viral Reservoirs

Metabolic Complications of HIV-1 Disease

HCV Co-Infection

HHV-8 and Kaposi's Sarcoma

CNS Reservoirs

Hyperlactatemia, Hepatotoxicity, and Other Adverse Effects of Antiretroviral Therapies

Osteopenia and Bone Metabolism Disorders

Abnormalities of Fat Distribution and Insulin Resistance

Cardiovascular Disease Risk

Antiretroviral Switch Studies for Metabolic Complications

Antiretroviral Therapy in Treatment-Naive and -Experienced Children

Immune Reconstitution in Children

Perinatal Transmission: Trends in Use of Preventive Interventions

Drug-Drug Interactions

Pharmacokinetics of Antiretroviral Drugs

Primary Infection

Advances in Antiretroviral Chemotherapeutics

Controlled Phase II Trial Assessing Three Doses of T-20 in Combination with Abacavir, Amprenavir, Low-Dose Ritonavir, and Efavirenz

HAART-Associated Bone Mineral Loss Through Increased Rate of Bone Turnover in Vertically HIV-Infected Children



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement